Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.68 USD | -3.72% | +6.46% | +108.12% |
May. 02 | Dyne Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 30 | Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+108.12% | 2.42B | |
+33.63% | 50.93B | |
-0.09% | 42.12B | |
+49.62% | 42.05B | |
-4.96% | 29.18B | |
+11.18% | 26.02B | |
-21.95% | 18.9B | |
+8.61% | 13.21B | |
+24.73% | 12.17B | |
+28.31% | 12.16B |
- Stock Market
- Equities
- DYN Stock
- News Dyne Therapeutics, Inc.
- Morgan Stanley Starts Dyne Therapeutics With Overweight Rating, $40 Price Target